Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.

Abstract excerpt

This review presents some therapeutic interventions actually considered in prostate cancer therapy to compensate constitutive activation of the PI3K/Akt signalling pathway induced, particularly, by mutations of PTEN gene. Special emphasis is placed on applicability of EGF-R tyrosine kinase, COX-2, PDK-1, mTOR and farnesyltransferase inhibitors.

Topics

Join the communities discussing this publication.

• 3-Phosphoinositide-Dependent Protein Kinases
• Cyclooxygenase 2 Inhibitors
• Farnesyltranstransferase
• Phosphatidylinositol 3-Kinases
• Phosphoinositide-3 Kinase Inhibitors